β³ Fetching live dividend data...
Home βΊ Calculator βΊ EFTRW Dividend Calculator 2026
eFFECTOR Therapeutics, Inc. Β· NASDAQ
Price: $0.00 Β· Annual div: $2.00/share Β· Frequency: quarterly Β· Payout ratio: 50% Β· Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in EFTRW β $1.698596171385972e+33M in 10 years Β· $141,507,228,780,196,900,000,000,000,000,000,000,000.00/month
eFFECTOR Therapeutics, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective translation regulator inhibitors aimed at combating cancer. Their primary investigational drug, Tomivosertib, is an orally administered small-molecule MNK inhibitor currently undergoing Phase 2b clinical trials. This candidate is being evaluated for its efficacy in patients suffering from metastatic non-small cell lung cancer. Additionally, the company is advancing zotatifin, another small molecule engineered to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 1/2 clinical studies for individuals with various solid tumors. Furthermore, it's being tested in a Phase 2a open-label expansion cohort, in conjunction with fulvestrant and abemaciclib, for patients afflicted with ER-positive breast cancer. eFFECTOR Therapeutics, Inc. also holds a research collaboration and licensing pact with Pfizer Inc., focused on co-developing eIF4E inhibitors. Established in 2012, the company maintains its corporate headquarters in Solana Beach, California.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. Β· Privacy Policy
Ready to invest? Open EFTRW position with:
Real after-tax yield depends on where you live and how you hold EFTRW.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| πΊπΈ Roth IRA / 401k | 0% | 333333.33% | 333330.53% | $33,333,333 / yr |
| πΊπΈ US Taxable (15%) β | 15% | 283333.33% | 283330.53% | $28,333,333 / yr |
| πΊπΈ US Taxable (20%) | 20% | 266666.66% | 266663.86% | $26,666,666 / yr |
| π¬π§ UK ISA | 0% | 333333.33% | 333330.53% | $33,333,333 / yr |
| π¬π§ UK Taxable | 8.75% | 304166.66% | 304163.86% | $30,416,666 / yr |
| π¨π¦ TFSA | 0% | 333333.33% | 333330.53% | $33,333,333 / yr |
| π¨π¦ CA Taxable | 25% | 250000.00% | 249997.20% | $25,000,000 / yr |
| π¦πΊ Super (pension) | 15% | 283333.33% | 283330.53% | $28,333,333 / yr |
| π¦πΊ AU Taxable | 30% | 233333.33% | 233330.53% | $23,333,333 / yr |
| π©πͺ DE Taxable | 26.375% | 245416.66% | 245413.86% | $24,541,666 / yr |
| π«π· FR Taxable | 30% | 233333.33% | 233330.53% | $23,333,333 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
EFTRW pays quarterly β 4 times per year. Next ex-div: TBD.
How EFTRW compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for EFTRW sourced from FMP /financial-growth endpoint β real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2024-06-13 | 800 | $1.38 | $1.1K | ||
| A-Award | 2024-06-13 | 800 | $1.38 | $1.1K | ||
| A-Award | 2024-06-13 | 800 | $1.38 | $1.1K | ||
| A-Award | 2024-06-13 | 800 | $1.38 | $1.1K | ||
| A-Award | 2024-06-13 | 800 | $1.38 | $1.1K | ||
| A-Award | 2024-06-13 | 800 | $1.38 | $1.1K | ||
| A-Award | 2024-05-15 | 1,387 | $1.68 | $2.3K | ||
| A-Award | 2024-05-15 | 1,806 | $1.68 | $3.0K | ||
| A-Award | 2024-02-19 | 2,000 | $11.32 | $22.6K | ||
| A-Award | 2024-02-19 | 2,000 | $11.32 | $22.6K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores β lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the EFTRW dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β
eFFECTOR Therapeutics, Inc. (EFTRW) is currently trading at $0.00, 100% below its 52-week high. The current dividend yield is 333333.33% based on an annual payout of $2.00 per share.
eFFECTOR Therapeutics, Inc. (EFTRW) is a healthcare stock currently trading at $0.00 with a dividend yield of 333333.33%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only β not financial advice.
Real users. No sign-up required to leave a review.
βFinally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.β
βI've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly β $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.β
βReally solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.β
βAs someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.β
βThe Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.β
Reviews reflect users' personal experiences. Not financial advice.
Leave a review β